연구성과로 돌아가기
2021 연구자 정보 (135 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Choi, Joon-Hyouk (Choi, JH) |
Jeju Natl Univ, Dept Internal Med, Sch Med, Jeju, South Korea Jeju Natl Univ Hosp, Dept Internal Med, Jeju, South Korea |
O-5940-2014 choi, jo |
|
[JCR상위 4.8] Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | sejjoo@jejunu.ac.kr; | ||
|
Choi, Seung-Hyuk (Choi, SH) |
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea |
AGZ-1893-2022 choi, sun ryoung |
|
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp; | ||
|
Choi, Yun-Jung (Choi, YJ) |
CymaBay Therapeut, Newark, CA USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Christianson, Dawn (Christianson, D) |
Arrowhead Pharmaceut Inc, Pasadena, CA USA |
|
|
[JCR상위 4.8] ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jhamilton@arrowheadpharma.com; | ||
|
Constantinescu, Alexandrina (Constantinescu, A) |
Fundeni Clin Inst, Bucharest, Romania |
|
|
[JCR상위 4.8] Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | john.flaherty@gilead.com; | ||
|
Dalekos, George (Dalekos, G) |
Gen Univ Hosp Larissa, Dept Med, Natl Expertise Ctr Greece Autoimmune Liver Dis, Larisa, Greece Gen Univ Hosp Larissa, Res Lab Internal Med, Natl Expertise Ctr Greece Autoimmune Liver Dis, Larisa, Greece |
|
|
[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com; | ||
|
Doerffel, Yvonne (Doerffel, Y) |
Charite, Berlin, Germany |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Flaherty, John F. (Flaherty, JF) |
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA |
|
|
[JCR상위 4.8] Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | john.flaherty@gilead.com; | ||
|
Forman, Lisa (Forman, L) |
Univ Colorado, Aurora, CO USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Freilich, Bradley (Freilich, B) |
Kansas City Res Inst, Kansas City, KS USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Gaggar, Anuj (Gaggar, A) |
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA |
|
|
[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jenny.yang@gilead.com; | ||
|
Gane, Edward (Gane, E) |
제1저자 | Univ Auckland, Auckland, New Zealand |
AGN-7071-2022 Gane, Edward |
|
[JCR상위 4.8] ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jhamilton@arrowheadpharma.com; | |
|
Gao, Bing (Gao, B) |
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA |
|
|
[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jenny.yang@gilead.com; | ||
|
Gheorghe, Liana (Gheorghe, L) |
Fundeni Clin Inst, Bucharest, Romania |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Goel, Aparna (Goel, A) |
Stanford Hosp, Stanford, CA USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; |
페이지 이동: